Prestige Consumer Healthcare (PBH) AI Stock Analysis

• Market Cap: $2.97B
• Dividend Yield: N/A
• Average Volume (3M): 456.76K
• Price to Earnings (P/E): 15.3
• Beta (1Y): 0.32
• Revenue Growth: -0.02%
• EPS Growth: -1.87%
• Country: US
• Employees: 600
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 1.07
• Shares Outstanding: 48,084,010
• 10 Day Avg. Volume: 504,397
• 30 Day Avg. Volume: 456,760
• PEG Ratio: 7.62
• Price to Book (P/B): 2.33
• Price to Sales (P/S): 3.76
• P/FCF Ratio: 17.56
• Enterprise Value/Market Cap: 1.35
• Enterprise Value/Revenue: 3.60
• Enterprise Value/Gross Profit: 6.38
• Enterprise Value/Ebitda: 11.20
• 1Y Price Target: $77.75
• Price Target Upside: 25.93% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 4.55
• Revenue Forecast (FY): $1.11B

• Rating: 66 Neutral
• Price Target: $66.00 ▲(6.90% Upside)

Prestige Consumer Healthcare's overall stock score is driven by its strong financial performance and reasonable valuation. However, the bearish technical indicators and challenges highlighted in the earnings call, such as declining revenue and supply constraints, weigh on the score. The company's strategic focus on e-commerce growth and market share expansion in the dental category are positive factors that could support future performance.

Positive Factors

E-commerce Growth

Sustained e-commerce growth indicates a strong digital presence and adaptability to consumer trends, supporting long-term revenue expansion.

DenTek Market Share Expansion

Significant market share gains in the dental category enhance competitive positioning and potential for sustained revenue growth.

Cash Flow Generation

Strong cash flow generation supports financial flexibility, enabling strategic investments and shareholder returns.

Negative Factors

Revenue Decline

Declining revenue poses challenges to growth, potentially impacting long-term profitability and market competitiveness.

Clear Eyes Supply Constraints

Supply constraints can lead to lost sales and reduced market share, affecting long-term brand strength and revenue.

Uncertain Retailer Inventory Patterns

Variable order patterns create revenue unpredictability, complicating planning and potentially impacting financial stability.

Prestige Consumer Healthcare Business Overview & Revenue Model

Company Description

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

How the Company Makes Money

Prestige Consumer Healthcare generates revenue primarily through the sale of its OTC healthcare products across various distribution channels, including retail, e-commerce, and pharmacy outlets. The company has a diverse range of revenue streams, with sales from both established brands and new product launches contributing significantly to its earnings. Key revenue streams include direct sales to retailers and wholesalers, as well as online sales through platforms like Amazon. Additionally, PBH engages in strategic partnerships with retailers, which can enhance brand visibility and accessibility, thereby driving sales. Seasonal demand, product innovation, and effective marketing strategies also play crucial roles in boosting the company's revenues.

Prestige Consumer Healthcare Financial Statement Overview

Summary

Prestige Consumer Healthcare demonstrates robust profitability with a strong gross profit margin and efficient cost management. However, recent negative revenue growth and a slight decline in free cash flow growth pose challenges. The balance sheet is stable with low leverage, but the company needs to focus on revitalizing sales growth.

Income Statement

Prestige Consumer Healthcare shows strong profitability with a consistent gross profit margin around 56% and a net profit margin of approximately 18% in the TTM period. However, revenue growth has been negative recently, indicating potential challenges in sales expansion. The EBIT and EBITDA margins remain healthy, reflecting efficient cost management.

Balance Sheet

The company's balance sheet is stable with a low debt-to-equity ratio of 0.03 in the TTM period, indicating low leverage. Return on equity is solid at around 11%, showcasing effective use of equity. However, the equity ratio is not explicitly provided, which could offer more insights into asset financing.

Cash Flow

Cash flow analysis reveals a slight decline in free cash flow growth, but the operating cash flow to net income ratio is strong at 1.96, indicating good cash generation relative to net income. The free cash flow to net income ratio is nearly 1, suggesting efficient conversion of earnings into cash.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.11B	1.14B	1.13B	1.13B	1.09B	943.37M
Gross Profit	625.98M	634.46M	624.45M	625.29M	620.65M	547.47M
EBITDA	356.93M	361.99M	373.86M	7.87M	358.84M	316.61M
Net Income	200.84M	214.60M	209.34M	-82.31M	205.38M	164.68M
Balance Sheet
Total Assets	3.44B	3.40B	3.32B	3.35B	3.67B	3.43B
Cash, Cash Equivalents and Short-Term Investments	119.11M	97.88M	46.47M	58.49M	27.18M	32.30M
Total Debt	1.04B	1.04B	1.14B	1.37B	1.51B	1.51B
Total Liabilities	1.62B	1.57B	1.66B	1.91B	2.09B	2.07B
Stockholders Equity	1.82B	1.83B	1.66B	1.45B	1.58B	1.36B
Cash Flow
Free Cash Flow	255.45M	243.29M	239.38M	221.93M	250.28M	213.36M
Operating Cash Flow	263.44M	251.51M	248.93M	229.72M	259.92M	235.61M
Investing Cash Flow	-18.16M	-17.45M	-20.11M	-11.58M	-256.51M	-22.24M
Financing Cash Flow	-176.58M	-182.07M	-241.01M	-185.85M	-7.57M	-279.42M

Prestige Consumer Healthcare Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 61.74
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBH, the sentiment is Positive. The current price of 61.74 is above the 20-day moving average (MA) of 60.46, above the 50-day MA of 60.74, and below the 200-day MA of 72.82, indicating a neutral trend. The MACD of 0.40 indicates Negative momentum. The RSI at 56.21 is Neutral, neither overbought nor oversold. The STOCH value of 73.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBH.

Prestige Consumer Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HSIC	74 Outperform	$9.11B	24.44	11.39%	―	3.51%	29.65%
PBH	66 Neutral	$2.97B	15.31	11.29%	―	-0.02%	-1.87%
CAH	66 Neutral	$48.22B	30.64	―	1.00%	4.37%	28.48%
MCK	62 Neutral	$101.24B	25.54	―	0.37%	17.23%	66.17%
GRDN	54 Neutral	$2.00B	49.55	25.85%	―	18.68%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OMI	42 Neutral	$219.66M	-0.16	-184.47%	―	-37.09%	-2639.44%

Prestige Consumer Healthcare Corporate Events

Prestige Consumer Healthcare Reports Q2 Fiscal 2026 Results

On November 6, 2025, Prestige Consumer Healthcare reported its financial results for the second quarter and first half of fiscal 2026, ending September 30, 2025. The company achieved revenues of $274.1 million in Q2, slightly below the previous year’s $283.8 million due to supply constraints in the Eye & Ear Care category. Despite this, the company exceeded its sales and earnings expectations, driven by strategic brand-building and share repurchases. The fiscal 2026 revenue outlook remains unchanged, but the adjusted diluted EPS outlook has been updated to the higher end of the previous range. The company continues to focus on rebuilding supply chain capacity for Clear Eyes and anticipates improvements in the second half of the fiscal year.